(Reuters) – Allergan Plc, created from the merger of Actavis and Allergan, reported a better-than-expected quarterly profit on strong sales of high-margin branded drugs, its biggest business. The merger brought signature drugs such as Botox anti-wrinkle treatment and eye drops Restasis under one roof, freeing Allergan to enter into a deal to sell its generics business to Teva Pharmaceuticals Industries Ltd. The company confirmed last week that it was approached by Pfizer Inc for a potential buyout. Allergan said revenue from branded products jumped 50 percent to $2. …
Original post:
Branded drugs help Botox-maker Allergan beat profit estimates
